002626.SHE Xiamen Kingdomway Group Co
- Market cap
- CNY 10.4B
- P/E
- 47.6x
- P/B
- 2.58x
- ROE
- 8.2%
- Dividend yield
- 2.63%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002626.SHE undervalued?
Graham number002626.SHE trades 133.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xiamen Kingdomway Group Co fundamental analysis
No fundamental analysis for Xiamen Kingdomway Group Co yet.
Xiamen Kingdomway Group Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xiamen Kingdomway Group Co
Xiamen Kingdomway Group Company engages in the manufacturing and sale of the nutrition and health products in China and internationally. The company also offers dietary supplements, functional foods, and sports nutrition. It offers its products under the Doctor's Best, Zipfizz, Kingdaway, Labrada, Prosupps, Wu Kun, Viactiv, RxSugar, LeanBody, and Jinlexin brands. It sells its products through online platforms and supermarkets. The company was formerly known as Xiamen Jindawe…
Full company profileXiamen Kingdomway Group Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xiamen Kingdomway Group Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.66B | 2.08B | 2.87B | 3.19B | 3.50B | 3.62B | 3.01B | 3.10B | 3.24B | 3.37B | 3.51B |
| Gross Profit | 684M | 991M | 1.49B | 1.51B | 1.82B | 1.71B | 1.14B | 1.14B | 1.24B | 1.32B | 1.39B |
| Operating Income | 350M | 560M | 803M | 581M | 1.13B | 937M | 312M | 356M | 482M | 533M | 557M |
| EBITDA | 481M | 670M | 971M | 802M | 1.30B | 1.10B | 515M | 539M | 663M | 647M | 527M |
| Net Income | 300M | 474M | 687M | 451M | 959M | 789M | 257M | 277M | 342M | 340M | 338M |
| EPS | 0.51 | 0.77 | 1.11 | 0.73 | 1.57 | 1.29 | 0.42 | 0.45 | 0.56 | 0.56 | 0.55 |
| Balance Sheet | |||||||||||
| Total Assets | 3.10B | 3.32B | 4.59B | 4.70B | 5.15B | 5.85B | 5.36B | 5.35B | 6.39B | 7.71B | 7.27B |
| Total Liabilities | 921M | 834M | 1.57B | 1.74B | 1.66B | 1.82B | 1.70B | 1.42B | 2.07B | 3.22B | 3.03B |
| Shareholders' Equity | 2.16B | 2.48B | 3.02B | 2.91B | 3.43B | 3.97B | 3.65B | 3.93B | 4.28B | 4.46B | 4.14B |
| Cash & Short-term Investments | 841M | 437M | 488M | 718M | 856M | 770M | 787M | 911M | 1.34B | 2.03B | 1.44B |
| Total Debt | 685M | 472M | 1.15B | 1.23B | 974M | 1.12B | 1.08B | 711M | 1.08B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 374M | 487M | 887M | 918M | 968M | 847M | 695M | 665M | 521M | 556M | - |
| Capital Expenditure | 20.6M | 90.0M | 79.1M | 176M | 250M | 345M | 162M | 252M | 365M | 230M | 935M |
| Free Cash Flow | 353M | 397M | 808M | 743M | 718M | 503M | 533M | 407M | 157M | 326M | -538M |
| Ratios | |||||||||||
| ROE | 13.8% | 19.1% | 22.8% | 15.5% | 28.0% | 19.9% | 7.1% | 7.0% | 8.0% | 7.6% | 8.2% |
| ROA | 9.7% | 14.3% | 15.0% | 9.6% | 18.6% | 13.5% | 4.8% | 5.2% | 5.4% | 4.4% | 4.7% |
| Net Profit Margin | 18.0% | 22.7% | 23.9% | 14.1% | 27.4% | 21.8% | 8.6% | 8.9% | 10.6% | 10.1% | 9.6% |
| Debt to Equity | 0.32x | 0.19x | 0.38x | 0.42x | 0.28x | 0.28x | 0.30x | 0.18x | 0.25x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Xiamen Kingdomway Group Co dividends
- Dividend yield
- 2.63%
- Forward dividend
- 0.40 CNY
- Payout ratio
- 80.8%
- Ex-dividend date
- Jun 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 275M | 0.45 | 80.8% |
| 2024 | CNY 146M | 0.24 | 42.6% |
| 2023 | CNY 159M | 0.26 | 57.5% |
| 2022 | CNY 366M | 0.60 | 142.2% |
| 2021 | CNY 366M | 0.60 | 46.4% |
| 2020 | CNY 366M | 0.60 | 38.2% |
| 2019 | CNY 492M | 0.80 | 109.1% |
| 2018 | CNY 274M | 0.44 | 39.8% |
| 2017 | CNY 140M | 0.23 | 29.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jun 9, 2015.
Who owns Xiamen Kingdomway Group Co
- Insiders 60.51%
- Institutions 1.85%
- Public & others 37.64%
- Shares outstanding 610M
- Free float 245M
Xiamen Kingdomway Group Co company profile
- Company name
- Xiamen Kingdomway Group Co
- Ticker
- 002626.SHE
- ISIN
- CNE1000018X4
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Oct 28, 2011
- Sector
- Consumer Defensive
- Industry
- Pharmaceuticals
- Employees
- 2,184
- Fiscal year end
- December
- Address
- No.299 Yangguang West Road, Xiamen, China, 361028
- Phone
- 86 59 2651 1111
- Website
- kingdomway.com
About Xiamen Kingdomway Group Co
Xiamen Kingdomway Group Company engages in the manufacturing and sale of the nutrition and health products in China and internationally. The company also offers dietary supplements, functional foods, and sports nutrition. It offers its products under the Doctor's Best, Zipfizz, Kingdaway, Labrada, Prosupps, Wu Kun, Viactiv, RxSugar, LeanBody, and Jinlexin brands. It sells its products through online platforms and supermarkets. The company was formerly known as Xiamen Jindawei Vitamin Co., Ltd. Xiamen Kingdomway Group Company was founded in 1997 and is based in Xiamen, China.
Xiamen Kingdomway Group Co management
5- Mr. Bin JiangChairman & GM · born 1967
- Mr. Hang HongCFO, Deputy GM & Non-Independent Director · born 1982
- Mr. Chen Jia LiangExecutive Deputy GM & Non-Independent Director · born 1964
- Mr. Zhan GuanghuangDeputy General Manager · born 1965
- Hong Yun HuangAccounting Supervisor